Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
์ข
๋ชฉ ์ฝ๋ TRDA
ํ์ฌ ์ด๋ฆEntrada Therapeutics Inc
์์ฅ์ผOct 29, 2021
CEODoshi (Dipal)
์ง์ ์183
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃOct 29
์ฃผ์One Design Center Place
๋์BOSTON
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02210
์ ํ18573051825
์น์ฌ์ดํธhttps://www.entradatx.com/
์ข
๋ชฉ ์ฝ๋ TRDA
์์ฅ์ผOct 29, 2021
CEODoshi (Dipal)